With the vision and aim to provide the best-quality drugs within time and at competitive prices, Murli Krishna Private Limited focuses on research and development, integration, and technological advancements in the pharmaceutical export industry

Since its inception, Murli Krishna Pharma has grown as one of the prominent brands in Asia. It provides solutions to optimize the delivery of pharmaceutical products.


Ms. Satya Vadlamani, an Electrical and Electronics Engineer by education, established Murli Krishna Pharmaceutical in 2004. She has more than 22 years of experience in marketing pharmaceutical products globally. She began her career in marketing at Armour Chemicals Limited in 1992, and later joined Biochem Synergy Limited.

In 1997, she established a pharma export company in 1997, purely as an indenting operation. The company was established under the name of Murli Krishna Exports. She switched over her operations from indenting to trading in 2003, due to business growth. Murli Krishna Pharma began exporting bulk semi-finished formulations and APIs in the form of pellets. Finally, in 2004, she decided to start her own venture under the name of Murli Krishna Pharma Private Limited to manufacture semi-finished formulations. Since then, she hasn’t looked back.


In a matter of a few years, Murli Krishna Pharma has carved a niche for itself. It has more than 200 clients with more than 64 international leading companies and a turnover exceeding US$ 6 Million.

There is a cumulative growth of over 60% from the last 3 years, proving their capabilities to win. Their manufacturing plant is approved by the European Union and the WHO for GMP Compliance.

The company’s Innovation Research Facility has received the Department of Scientific and Industrial Research (DSIR)’s approval. Murli Krishna Pharma Private Limited makes best quality products following WHO-GMP guidelines. This dedication towards quality enables the firm to deliver world-class products.


Murli Krishna Pharma believes that the strength of any successful organization depends on its people, and the people are the backbone of the organization. It strives to maximize the operational freedom of each employee. The organization provides a modern environment that facilitates participation, learning, and out-of-the-box thinking. The corporate culture of the company is strongly influenced by teamspirit, which keeps the employees united while they work towards a common goal. Murli Krishna Pharma is managed by a proficient Board of Directors, who are assisted by a team of qualified professionals in every department.


The firm has expanded in terms of rendering services as a Contract Research and Manufacturing Services (CRAMS) provider. Its encapsulation covers micro pellets and this expertise is being extended to the development of nanoparticles. The organization has a world-class manufacturing facility for pellets, micro-pellets and granules approved by the regulatory authorities of developed countries. Manufacturing prefinished formulations i.e., pellets using aqueous based technology and avoiding use of solvents completely are also undertaken by the firm. The company has 3 potential IPRs. It develops platform technology and implements the same. InvAscent, a healthcare private equity firm invested INR 70 crore in Murli Krishna Pharma in June 2020.


Murli Krishna Pharma was featured in the ‘100 Most Admired Brands 2020’ as a leading brand at the 8th White Page Leadership Conclave. The company has been awarded the ‘Up-and-Coming Brand in Drug Delivery System’ at the GLOBE Platinum Awards 2016.